File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice
  • Basic View
  • Metadata View
  • XML View
TitleTherapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice
 
AuthorsZheng, B1
Ng, MH1
He, LF2
Yao, X2
Chan, KW1
Yuen, KY1
Wen, YM2
 
KeywordsHepatitis B virus
Immune tolerance
Therapeutic vaccine
 
Issue Date2001
 
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
CitationVaccine, 2001, v. 19 n. 30, p. 4219-4225 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0264-410X(01)00158-X
 
AbstractTherapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved.
 
ISSN0264-410X
2013 Impact Factor: 3.485
 
DOIhttp://dx.doi.org/10.1016/S0264-410X(01)00158-X
 
ISI Accession Number IDWOS:000170090200017
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorZheng, B
 
dc.contributor.authorNg, MH
 
dc.contributor.authorHe, LF
 
dc.contributor.authorYao, X
 
dc.contributor.authorChan, KW
 
dc.contributor.authorYuen, KY
 
dc.contributor.authorWen, YM
 
dc.date.accessioned2012-05-29T06:11:53Z
 
dc.date.available2012-05-29T06:11:53Z
 
dc.date.issued2001
 
dc.description.abstractTherapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationVaccine, 2001, v. 19 n. 30, p. 4219-4225 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0264-410X(01)00158-X
 
dc.identifier.doihttp://dx.doi.org/10.1016/S0264-410X(01)00158-X
 
dc.identifier.epage4225
 
dc.identifier.hkuros62046
 
dc.identifier.isiWOS:000170090200017
 
dc.identifier.issn0264-410X
2013 Impact Factor: 3.485
 
dc.identifier.issue30
 
dc.identifier.pmid11457548
 
dc.identifier.scopuseid_2-s2.0-0035919599
 
dc.identifier.spage4219
 
dc.identifier.urihttp://hdl.handle.net/10722/148265
 
dc.identifier.volume19
 
dc.languageeng
 
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVaccine
 
dc.relation.referencesReferences in Scopus
 
dc.rightsVaccine. Copyright © Elsevier Ltd.
 
dc.subject.meshAnimals
 
dc.subject.meshAntigen-Antibody Complex - Immunology
 
dc.subject.meshCytokines - Biosynthesis
 
dc.subject.meshDna, Recombinant - Immunology
 
dc.subject.meshHepatitis B - Therapy
 
dc.subject.meshHepatitis B Antibodies - Immunology
 
dc.subject.meshHepatitis B Surface Antigens - Blood - Immunology
 
dc.subject.meshHepatitis B Vaccines - Therapeutic Use
 
dc.subject.meshLiver - Pathology - Virology
 
dc.subject.meshMice
 
dc.subject.meshMice, Inbred C57bl
 
dc.subject.meshMice, Transgenic
 
dc.subject.meshT-Lymphocytes, Cytotoxic - Immunology
 
dc.subjectHepatitis B virus
 
dc.subjectImmune tolerance
 
dc.subjectTherapeutic vaccine
 
dc.titleTherapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zheng, B</contributor.author>
<contributor.author>Ng, MH</contributor.author>
<contributor.author>He, LF</contributor.author>
<contributor.author>Yao, X</contributor.author>
<contributor.author>Chan, KW</contributor.author>
<contributor.author>Yuen, KY</contributor.author>
<contributor.author>Wen, YM</contributor.author>
<date.accessioned>2012-05-29T06:11:53Z</date.accessioned>
<date.available>2012-05-29T06:11:53Z</date.available>
<date.issued>2001</date.issued>
<identifier.citation>Vaccine, 2001, v. 19 n. 30, p. 4219-4225</identifier.citation>
<identifier.issn>0264-410X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/148265</identifier.uri>
<description.abstract>Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-&#947; produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. &#169; 2001 Elsevier Science Ltd. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Ltd. The Journal&apos;s web site is located at http://www.elsevier.com/locate/vaccine</publisher>
<relation.ispartof>Vaccine</relation.ispartof>
<rights>Vaccine. Copyright &#169; Elsevier Ltd.</rights>
<subject>Hepatitis B virus</subject>
<subject>Immune tolerance</subject>
<subject>Therapeutic vaccine</subject>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Antigen-Antibody Complex - Immunology</subject.mesh>
<subject.mesh>Cytokines - Biosynthesis</subject.mesh>
<subject.mesh>Dna, Recombinant - Immunology</subject.mesh>
<subject.mesh>Hepatitis B - Therapy</subject.mesh>
<subject.mesh>Hepatitis B Antibodies - Immunology</subject.mesh>
<subject.mesh>Hepatitis B Surface Antigens - Blood - Immunology</subject.mesh>
<subject.mesh>Hepatitis B Vaccines - Therapeutic Use</subject.mesh>
<subject.mesh>Liver - Pathology - Virology</subject.mesh>
<subject.mesh>Mice</subject.mesh>
<subject.mesh>Mice, Inbred C57bl</subject.mesh>
<subject.mesh>Mice, Transgenic</subject.mesh>
<subject.mesh>T-Lymphocytes, Cytotoxic - Immunology</subject.mesh>
<title>Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/S0264-410X(01)00158-X</identifier.doi>
<identifier.pmid>11457548</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0035919599</identifier.scopus>
<identifier.hkuros>62046</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0035919599&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>19</identifier.volume>
<identifier.issue>30</identifier.issue>
<identifier.spage>4219</identifier.spage>
<identifier.epage>4225</identifier.epage>
<identifier.isi>WOS:000170090200017</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. null